Targacept Announces Decision by AstraZeneca to Advance AZD1446 in Alzheimer’s Disease
Friday, January 6th, 2012Targacept, Inc. , a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that AstraZeneca has informed the company that it plan
Read the original:
Targacept Announces Decision by AstraZeneca to Advance AZD1446 in Alzheimer’s Disease